Navigation Links
Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain
Date:5/18/2009

es across all domains "sometimes," "often" or "always." After treatment this shifted dramatically such that 60-80% of subjects said "never" or "rarely" to these same EHP-5 questions. Equally notable is the observation that much of this improvement was sustained post-treatment.

Estradiol and Ovulation: The previously reported pharmacodynamic effect of elagolix was confirmed. Median estradiol values were maintained in the low baseline range while on treatment and, most importantly, were not lowered to values that would be associated with hot flashes or clinically significant bone loss. As reported, Week 24 median estradiol was 47 pg/ml for elagolix once daily and 29 pg/ml for elagolix twice daily. At Week 48, the median values for the groups were normal at 80 pg/ml and 84 pg/ml, respectively. The mean time to ovulation post-treatment was 24 days for women who had been randomized to elagolix and >90% of subjects had evidence of ovulation within 4 weeks of stopping. Prolonged suppression of ovulation was documented, even out to Week 48 in the DMPA subjects who also reported frequent spotting and irregular vaginal bleeding.

Safety and Tolerability: Assessment of vital signs, physical examination, electrocardiogram, and clinical laboratory tests did not reveal any safety concerns. Adverse events that were reported were generally mild and transient in nature and not usually associated with study discontinuation. The most common adverse events in this trial were consistent with what we have observed in the other elagolix trials including headache (approximately 20% of subjects reported 1 or more headaches during the 6 months of treatment) and nausea (approximately 15% of subjects reported 1 or more episode of nausea). The most common reason for premature discontinuation from the study was withdrawal of consent (i.e., subject moved, work conflict, etc). Seven subjects withdrew from the study with excessive, prolonged or bre
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2009 Financial Results
2. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
3. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
4. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
5. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
6. Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International Conference
7. GNAX/AtlantaNAP Announces Newest Client, Health Information Designs
8. AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
9. AMR Research Announces Final Agenda for Sold-Out Supply Chain Executive Conference
10. International Student Insurance Announces Website Redesign
11. Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Thompson HealthDay Reporter ... into the United States -- along with Angelina Jolie,s ... have highlighted cracks in the nation,s public health defense ... report released Thursday. Half of U.S. states are ... disease outbreaks. That was the main conclusion of the ...
(Date:12/19/2014)... The global magnetic resonance imaging (MRI) ... is saturated with numerous players developing innovative technologies. ... as non-invasive nature, MRI systems have seen continued ... healthcare market. Rapid advances in the field imaging ... have greatly expanded the potential of therapeutic applications. ...
(Date:12/19/2014)... 2014 Pain Free Living a leader ... announce a new Superior magnetic necklace using ... the strongest neodymium magnets for the fastest pain relief ... the Superior Magnetics brand for the fastest relief by ... magnetic therapy using Superior Magnetic Jewelry at fairs and ...
(Date:12/19/2014)... Slone Partners , a ... healthcare information technology, and laboratory testing industries, has ... Operating Officer. The announcement comes after a year ... strengthened presence in Boston and several new additions ... breathes the client experience," said Adam Slone, Chief ...
(Date:12/19/2014)... Consilium Staffing, Your Partner in ... for Federal Health Professionals annual meeting in Washington, ... military and federal healthcare providers. , In ... Business Engagement (NVSBE) conference last week in Atlanta, ... vital solution in addressing our nation’s shortage of ...
Breaking Medicine News(10 mins):Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 2Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 4Health News:New Superior Magnetic Necklace Relieves Migraine Headache 2Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Consilium Staffing Increasing Awareness of Locum Tenens through Conference Appearances 2
... Back New Provider Non-Discrimination Safeguards to Ensure Patient Access ... WASHINGTON, Dec. 4 The American Optometric Association (AOA), ... eye and vision care in America, and eleven other ... (PARCA) today called on President-elect Barack Obama and Congressional ...
... Income Trust (NYSE: UHT ) announced today that ... Marc D. Miller, Senior Vice,President of Universal Health Services, Inc. ... of experience in healthcare leadership roles. He has,served as ... Division,since 2007 and prior to that, served as Vice President ...
... ease sickle-cell disease and thalassemia , ... ... Boston ( www.childrenshospital.org ) and Dana-Farber Cancer Institute have identified ... form of hemoglobin normally made only before birth or by ...
... 4 Dr. Stephen Joffe, Craig Joffe, and,Alan Buckey ... the U.S.,Securities and Exchange Commission. The group previously ... (Nasdaq: LCAV ), which,operates 77 LasikPlus fixed-site ... States. Dr. Joffe is the founder and former ...
... a Common Factor?" , , ... call into question the safety of the Centers for Disease ... concurrently. , , Mitochondrial ... in PLOS One by investigators from the Cleveland Clinic, Johns ...
... of vigorous activity a week , , THURSDAY, Dec. 4 ... in the United States last year met the 2008 ... those people met the Healthy People 2010 physical activity ... , According to the 2008 guidelines, released in October ...
Cached Medicine News:Health News:AOA-Led Group Urges Obama to Increase Health Care Access, Affordability by Combating Provider Discrimination 2Health News:AOA-Led Group Urges Obama to Increase Health Care Access, Affordability by Combating Provider Discrimination 3Health News:Turning back the Clock in Inherited Anemias 2Health News:Turning back the Clock in Inherited Anemias 3Health News:Turning back the Clock in Inherited Anemias 4Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 2Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 3Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 4Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 5Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 6Health News:Researchers & Department of Defense Question Multiple Vaccine Administration 2Health News:Almost Two-Thirds of Americans Meet Exercise Guidelines 2Health News:Almost Two-Thirds of Americans Meet Exercise Guidelines 3
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group ... the United States will increase to a ... be primarily driven by expansion in the large direct ... devices will be increasingly adopted due to the advantages ... Other key findings from Decision Resources Group,s coverage ...
(Date:12/19/2014)... Ky. , Dec. 18, 2014 Baptist Health ... States to receive full Atrial Fibrillation with Electrophysiology ... Care (SCPC). Atrial fibrillation is the most common ... that in some cases can lead to stroke and possible ... United States have atrial fibrillation and the numbers ...
(Date:12/19/2014)... LYON, France , Dec. 19, 2014 ... ) and Adocia (Euronext Paris: FR0011184241 – ADOC) today ... ultra-rapid insulin, known as BioChaperone Lispro, for treatment in ... Lispro relies on Adocia,s proprietary BioChaperone® technology and is ... Adocia will develop BioChaperone Lispro with the goal of ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... COCONUT GROVE, Fla., April 9, 2012 Med-Tek a developer ... for patients, physicians, employers and their constituents today announces ... According to the United ... through 2004 individuals suffering from ...
... 2012 C8 MediSensors, Inc. ( www.c8medisensors.com ), the ... with diabetes, announced today that it has filed for ... Glucose Monitor™ in Europe. The monitor is currently an ... "The European Union has over 30 ...
Cached Medicine Technology:Med-Tek Launches the First Evidenced Based Opioid Management Program (OMP) 2C8 MediSensors Files for CE Mark Approval, Advancing Plans for 2012 Product Introduction In Europe 2
For the quantitative determination of Gamma-GT in serum. Kinetic Reaction measured at 405 nm. Linearity: 600 IU/L at 37C....
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for eight hours. Wavelength: 650 nm. Linearity: 16 m...
For the quantitative determination of calcium in serum. Endpoint Reaction Product measured at 570 nm Linearity: 20 mg/dl...
Alanine Aminotransferase (ALT) reagent is used for the quantitative determination of alanine aminotransferase (Glutamate pyruvate transaminase, SGPT) in human serum....
Medicine Products: